Benzamide STING Agonists With Better Permeability and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current STING agonists face challenges with poor cell membrane permeability and metabolic instability, limiting their effectiveness as immunotherapeutics for viral diseases and cancers.
Innovation Solution
Development of functionalized benzamide derivatives that act as cGAS-STING pathway agonists, inducing proinflammatory cytokine responses in a human STING-dependent manner.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cyclic dinucleotides are used as STING agonists, then immune response activation is achieved, but cell membrane permeability is poor
Solution Approach 1:
The patent uses cell-permeable delivery systems (liposomes, exosomes, nanoparticles) as intermediaries to transport cyclic dinucleotides across the cell membrane. These delivery vehicles solve the permeability problem by providing a carrier that can penetrate biological barriers and release the agonist inside the cell, thereby maintaining immune activation efficacy while overcoming the delivery barrier.
Solution Approach 2:
The patent modifies the chemical structure of cyclic dinucleotides by creating analogs with altered molecular properties (such as 2′3′-cGAMP derivatives) that have improved membrane permeability. By changing physical-chemical parameters like lipophilicity and molecular size, the compounds gain better cell penetration capability while retaining their ability to activate STING and induce immune responses.
2Reliability
If cyclic dinucleotides are used as STING agonists, then immune response activation is achieved, but metabolic stability is poor
Solution Approach 1:
The patent creates metabolically stable analogs of cyclic dinucleotides by modifying their chemical structure. Specific structural changes (such as adding fluorine atoms, modifying sugar moieties, or creating non-natural nucleotide analogs) protect the molecules from enzymatic degradation by nucleotide phosphodiesterases and other metabolic enzymes, thereby extending their half-life and maintaining stable immune activation.
Solution Approach 2:
The patent employs composite delivery systems that combine cyclic dinucleotides with protective polymers or stabilizing agents. These composite formulations shield the fragile cyclic dinucleotide structure from metabolic degradation in the bloodstream and cellular environment, allowing the active compound to reach its target and exert immunotherapeutic effects without rapid breakdown.
3Reliability
If existing STING agonists are used, then antiviral and antitumor effects are observed, but pharmacological properties are limited
Solution Approach 1:
The patent develops STING agonists with enhanced multi-functionality and broader pharmacological profiles. The compounds not only activate STING for antiviral and antitumor immunity but also exhibit improved pharmacokinetic properties (absorption, distribution, metabolism, excretion), reduced off-target toxicity, and potential activity against multiple pathogen types and cancer indications, making them more versatile therapeutic agents.
Solution Approach 2:
The patent optimizes various pharmacological parameters of STING agonists including bioavailability, tissue distribution, half-life, and therapeutic index. By adjusting molecular properties and delivery mechanisms, the compounds achieve better balance between efficacy and safety, enabling systemic administration and sustained immune activation with reduced dosing frequency and lower toxicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The benzamide derivatives effectively stimulate the STING pathway, enhancing immune responses against viral infections and tumors, offering improved pharmacological properties over existing STING agonists.
Implementation Method 1
Binding of the cyclic dinucleotides to STING induces its dimerization and translocation from ER membrane to perinuclear vesicles
Implementation Method 2
Activation of these signaling pathways induces the expression of type I and type III interferons as well as other inflammatory cytokines
Data Source
AI summary
Pharmaceutical compositions of the invention comprise functionalized benzamide derivatives useful as cyclic GMP-AMP synthase-Stimulator of interferon gene (cGAS-STING) pathway agonists, and useful for treating viral diseases and boost antitumor immunity.